SCHEMBL7250352

SCHEMBL7250352

COc1ccc(-c2ccc(F)cc2[N+](=O)[O-])cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.51
MAPT P10636 6/20 0.45
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 3/20 0.45
TDP1 Q9NUW8 4/20 0.45
ATM Q13315 1/20 0.45
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HTT P42858 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
PTGES O14684 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
APP P05067 1/20 0.43
XDH P47989 1/20 0.43
SQOR Q9Y6N5 1/20 0.43
GSK3B P49841 1/20 0.43
SYK P43405 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2336139 0.87 HTR7 (0.56) HTR7MAPTALDH1A1KDM4ETDP1
SCHEMBL29563324 0.85 TDP1 (0.55) MAPTALDH1A1TDP1ATMPTGES
SCHEMBL15379986 0.85 TDP1 (0.55) MAPTALDH1A1TDP1ATMPTGES
SCHEMBL2955704 0.83 ALDH1A1 (0.54) HTR7MAPTALDH1A1KDM4ELMNA
SCHEMBL9031419 0.83 TDP1 (0.49) MAPTALDH1A1TDP1ATML3MBTL1
SCHEMBL21708340 0.82 HTR7 (0.48) HTR7MAPTALDH1A1KDM4ETDP1
SCHEMBL10134271 0.82 HTR7 (0.51) HTR7MAPTALDH1A1KDM4ETDP1
SCHEMBL11188343 0.81 HTR7 (0.54) HTR7MAPTALDH1A1KDM4ETDP1
SCHEMBL18607487 0.81 HTR7 (0.48) HTR7MAPTALDH1A1KDM4ETDP1
SCHEMBL2949599 0.80 ERN1 (0.51) MAPTATMHTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030040538-A1 Novel substituted tricyclic compounds ASAHI-KASEI KABUSHIKI KAISHA (JP) 2003-02-27 US disclosed
EP-1238973-A1 NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS Asahi Kasei Kabushiki Kaisha (JP) 2002-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040538-A1 Novel substituted tricyclic compounds CPT1A, CBR1, NR1H3 HTR7 1431/4885MAPT 4835/4885ALDH1A1 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.